In December 2024, Regulus met with the FDA for an End-of-Phase 1 meeting where they reached alignment on the acceptability of the program's CMC, non-clinical and clinical pharmacology plans and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback